| DC23660 |
AK106-001616(AK 106-001616) |
AK106-001616 (AK 106-001616) is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) with IC50 of 3.8 nM (human cPLA2 enzyme). |
|
| DC21991 |
AK306 |
AK306 is a small molecule clathrin heavy chain (CLTC/CHC) binding compound that induces arrest and apoptosis of the HCT116 colon cancer cell line with EC50 of 50 nM. |
|
| DC23789 |
AK778
Featured
|
AK778 (Col001) is a small-molecule compound that inhibits the interaction of Hsp47 with collagen, competitively inhibits the interaction and causes the inhibition of collagen secretion by destabilizing the collagen triple helix. . |
|
| DC20649 |
AKB-9778
Featured
|
AKB-9778 is a potent, selective inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP) with IC50 of 17 pM. |
|
| DC12158 |
AKOS B018304
Featured
|
AKOS B018304 is an arylalkylidene derivative, with polar substitution at para-position. |
|
| DC10941 |
AKR1C3 inhibitor KV-37 |
AKR1C3 inhibitor KV-37 is a potent, isoform selective and metabolically stable inhibitor of Aldo-keto reductase 1C3 (AKR1C3) with IC50 of 66 nM, displays 109-fold selectivity over AKR1C2. |
|
| DC9677 |
AL 082D06(D-06)
Featured
|
AL 082D06(D-06) is the first selective, nonsteroidal glucocorticoid receptor (GR) antagonist with Ki of 210 nM, exhibits excellent selectivity against AR, PR, MR and ER(Ki > 10 uM). |
|
| DC20260 |
AL-335
Featured
|
AL-335 is a potent inhibitor of hepatitis C virus (HCV) NS5B polymerase with IE50 values as low as 70 nM. AL-335 is potentially useful for the Treatment of Hepatitis C Infection. AL-335 demonstrated high levels of the nucleoside triphosphate in vitro in primary human hepatocytes and Huh-7 cells as well as in dog liver following a single oral dose. AL-335 was selected for the clinical development where it showed promising results in phase 1 and 2 trials. |
|
| DC21111 |
AL-9 |
AL-9 is a small molecule HCV replication inhibitor with EC50 of 0.29 and 0.75 uM for genotype 1b and 2a, inhibits purified PI4KIIIα with IC50 of 0.57 uM. |
|
| DC20652 |
ALB-127158 |
ALB-127158 is a potent (IC50=7 nM), selective, non-peptide antagonist of MCHR1 (Melanin-concentrating hormone receptor 1) for treatment of obesity.. |
|
| DC10780 |
ALB-127158(a)
Featured
|
ALB-127158A, also known as ALB-127158(a), is a MCH1 antagonist for the treatment of obesity. |
|
| DCAPI1243 |
Albendazole(Albenza) |
Albendazole(Albenza) |
|
| DC20174 |
Albiglutide
Featured
|
Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist). |
|
| DC21993 |
ALDH1A inhibitor 673A |
ALDH1A inhibitor 673A (ALDH1Ai 673A) is a potent, selective, pan-ALDH1A inhibitor with IC50 of 246, 230 and 348 nM for ALDH1A1, ALDH1A2 and ALDH1A3, respectively. |
|
| DC20653 |
ALE-0540
Featured
|
ALE-0540 is a nerve growth factor (NGF) antagonist that inhibits the binding of NGF to TrkA or both p75 and TrkA with IC50 of 5.88 and 3.72 uM, respectively. |
|
| DCAPI1034 |
Alendronate (Fosamax) |
Alendronate (Fosamax) |
|
| DC22492 |
Alexamorelin
Featured
|
Alexamorelin is a synthetic growth hormone (GH) secretagogue. |
|
| DC12389 |
Alflutinib
Featured
|
Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.The Alflutinib free base form is not stable, so we make it the mesylate s |
|
| DC22211 |
ALG1001 (Risuteganib)
Featured
|
ALG1001 (Risuteganib, ALG-1001) is a first-in-class, RGD class oligopeptide that inhibits integrin receptors (αvβ3, αvβ5, and α5β1) associated with angiogenesis; ALG1001 inhibits an integrin-mediated pathway of the vitreoretinal interface, connecting the posterior aspect of the vitreous with the internal limiting membrane of the retina. In blocking this pathway, ALG-1001 helps to achieve vitreous breakdown and separation from the retina. |
|
| DC20056 |
Alicapistat (ABT-957) |
Alicapistat (ABT-957) is an orally active selective inhibitor of human calpains 1 and 2 for the potential use in the treatment of Alzheimer's disease (AD). |
|
| DC23405 |
Alizapride |
Alizapride (MS 5080) is a dopamine D2 antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting.. |
|
| DC23489 |
Alizapride hydrochloride |
Alizapride (MS 5080) is a dopamine D2 antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting.. |
|
| DC23092 |
Alizarin |
Alizarin has a selective and effective inhibitory activity towards cancerous cells, it acts through the inhibition of ERK phosphorylation and cell cycle arrest in the S-phase. |
|
| DC9338 |
ALK inhibitor 1
Featured
|
ALK inhibitor 1 is a novel and selective inhibitor for the ALK kinase. |
|
| DC9339 |
ALK inhibitor 2
Featured
|
ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase. |
|
| DC10582 |
Diroximel Fumarete(ALKS-8700)
Featured
|
ALKS-8700 also known as diroximel fumarate, is a prodrug of monomethyl fumarate in a controlled-release formulation that rapidly and efficiently converts to MMF in the body. |
|
| DC21668 |
ALLO-2
Featured
|
ALLO-2 is a potent small molecule Smoothened (Smo) antagonist that inhibits Smo agonist Hh-Ag1.5-induced luciferase expression in TM3-Gli-Luc cells with IC50 of 6 nM. |
|
| DC12226 |
Alloepipregnanolone |
Alloepipregnanolone, a pregnane with anesthetic, hypnotic, and sedative properties, interferes with the development of rapid tolerance to the anxiolytic effect of ethanol. |
|
| DC8945 |
Allopurinol |
Allopurinol (Zyloprim) is a xanthine oxidase inhibitor with an IC50 of 7.82±0.12 μM. |
|
| DCAPI1097 |
Allopurinol Sodium (Aloprim)
Featured
|
Allopurinol sodium is a potent xanthine oxidase inhibitor (IC50 values of 0.2 to 50 μM). Allopurinol sodium can be used for the research of hyperuricemia and gout. Antileishmanial effect[1][2]. |
|
